New combo therapy aims to shrink liver tumors in Hard-to-Treat patients

NCT ID NCT07122089

Recruiting now Disease control Sponsor: Center Eugene Marquis Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a two-step treatment for people with advanced liver cancer that has spread into the main liver blood vessel (portal vein). First, patients receive targeted radiation (SIRT) to shrink the tumor from inside the liver. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system attack any remaining cancer. The goal is to see if this combination shrinks tumors better than current treatments. About 80 adults whose cancer has not spread outside the liver will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA NON-RESECTABLE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Grenoble
ACTIVE_NOT_RECRUITING

Grenoble, France
CHU de Lille
ACTIVE_NOT_RECRUITING

Lille, France
CHU de Montpellier
ACTIVE_NOT_RECRUITING

Montpellier, France
CHU de Nice
ACTIVE_NOT_RECRUITING

Nice, France
Centre Eugène Marquis
RECRUITING

Rennes, France

Contact Phone: •••-•••-•••• Email: •••••@•••••
La Timone
NOT_YET_RECRUITING

Marseille, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.